Background: Hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer. We performed a systematic review to compare safety, efficacy and effectiveness of degarelix, a new gonadotropin-releasing hormone (GnRH) antagonist (blocker), versus gonadotropin-releasing hormone (GnRH) agonists. Methods: MEDLINE, Web of Science and the Cochrane librar...

objective(s): we performed a phase iia clinical trial of trans-1-amino-3-18ffluoro-cyclobutane carboxylic acid (anti-18f-facbc), a synthetic amino acid analog for pet, in patients with metastatic prostate cancer. methods: the study subjects consisted of 10 untreated prostate cancer patients having lymph node and/or bone metastasis. five patients underwent whole-body pet 5 and 30 min after intra...

background: to analyze the dosimetric and radio biologic advantages between intensity modulated radiotherapy (imrt) and 3 dimensional conformal radiotherapy (3dcrt) and selection of optimal photon energy for imrt treatments. material and methods: 24 patients with localized prostate carcinoma were planned for 3dcrt and imrt techniques. radiation dose of 54 gy with 2 gy/fraction, was planned to p...

background : this study retrospectively evaluated the prognostic factors and treatment outcome of patients with hormone-refractory prostate cancer who received chemotherapy. methods :we reviewed records of hormone-refractory prostate cancer patients who received chemotherapy between december 2004 and may 2011 at the clinical oncology and nuclear medicine department, mansoura university and the ...

Background: stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer. However, prostate-specific antigen (PSA) kinetics after SBRT has not been well characterized. The objective of the current study is to analyze the rate of PSA decline and PSA nadir following hypofractonated SBRT in localized prostate cancer. Materials and Methods: From 2008...

Prostate cancer is a devastating disease for which current therapies are inadequate. Various lines of evidences have suggested the 5-lipoxygenase (5-LOX) pathway and the leukotriene receptor pathway are potential targets for prevention or treatment of Prostate cancer. Thus, search for new anti-cancer drugs targeting 5-LOX and leukotriene is very essential and important. The objective of the pre...

Leiomyosarcoma is a rare entity in prostate but it is the most common type of prostate sarcomas in adult patients. In most reported series the prognosis is poor and the median survival is about 15-18 months. Hereby we present a 72 years old man who received combined modality treatment including radical surgery followed by adjuvant chemotherapy and radiotherapy. He has been well for 14 months, b...

Erectile dysfunction (ED) is a common complication of prostate cancer treatment. In the second this two-part series on management erectile following treatment for localised cancer, authors discuss therapeutic options available ED after and their advantages disadvantages.

BACKGROUND The diagnosis and treatment of prostate cancer is a controversial topic. Until recently there has not been a reliable imaging mo-dality for identification of cancer within the prostate. New evidence suggests that multiparametric magngenetic resonance im-aging (MRI) has the potential to improve the diagnosis and treatment of prostate cancer. OBJECTIVE This article explains the poten...